Costs to treat heart failure expected to more than double by 2030

American Heart Association Policy Statement

2013-04-24

(Press-News.org) By 2030, you — and every U.S. taxpayer — could be paying $244 a year to care for heart failure patients, according to an American Heart Association policy statement. The statement, published online in the American Heart Association journal Circulation: Heart Failure, predicts: The number of people with heart failure could climb 46 percent from 5 million in 2012 to 8 million in 2030. Direct and indirect costs to treat heart failure could more than double from $31 billion in 2012 to $70 billion in 2030. "If we don't improve or reduce the incidence of heart failure by preventing and treating the underlying conditions, there will be a large monetary and health burden on the country," said Paul A. Heidenreich, M.D., M.S., professor of medicine at Stanford University School of Medicine and director of the Chronic Heart Failure Quality Enhancement Research Initiative at the VA Health Care System in Palo Alto, Calif. "The costs will be paid for by every adult in this country, not just every adult with heart failure." The rising incidence is fueled by the aging population and an increase in the number of people with conditions like ischemic heart disease, hypertension and diabetes — contributors to the development of heart failure. Being older, a smoker, a minority or poor are also risk factors. "Awareness of risk factors and adequately treating them is the greatest need," Heidenreich said. Heart failure is a life-threatening condition that occurs when the heart has been weakened from heart disease, high blood pressure, diabetes and other underlying conditions, and can no longer pump enough oxygen- and nutrient-rich blood throughout the body. Heart failure is the leading cause of hospitalization for Americans over age 65. Patients are often fatigued and have breathing problems, as the heart enlarges and pumps faster to try to meet the body's needs. "Heart failure is a disease of the elderly," Heidenreich said. "Because our population is aging, it will become more common and the cost to treat heart failure will become a significant burden to the United States over the next 20 years unless something is done to reduce the age-specific incidence." The statement includes recommendations on lessening the impact of heart failure and managing the rising number of Americans with the condition. These include: More effective dissemination and use of guideline-recommended therapy to prevent heart failure and improve survival. Improving the coordination of care from hospital to home to achieve better outcomes and reduce rehospitalizations. Specialized training for physicians, nurses, pharmacists and other healthcare professionals to meet the future demands of advanced heart failure care. Reducing disparities for heart failure prevention and care among racial, ethnic, and socioeconomic subgroups to help close the gap in health outcomes. Increasing access to palliative and hospice care, for patients with advanced-stage heart failure. "We have the solutions we need to change the course of heart failure in this country, but we must take steps now to reverse the trend," said American Heart Association CEO Nancy Brown. "If we treat patients using existing guidelines, improve care transitions, adequately train our healthcare workforce and reduce disparities in the health outcomes of specific populations, we can lessen the burdens of heart failure." "For those Americans in the last stages of heart failure, we must also increase access to palliative and hospice care to reduce the suffering of their final years." The statement doesn't examine the impact of provisions of the Affordable Care Act. If laws allow more people to have access to health care, it could lower the rates of heart failure and ultimately costs as people will have access to preventive care, Heidenreich said. Also, being an ethnic minority and of a lower socio-economic status were both cited as risk factors for heart failure, so more access to health care may help reduce overall risk. ### Co-writers of the statement are: Nancy M. Albert, Ph.D., R.N.; Larry A. Allen, M.D., M.H.S.; David A. Bluemke, M.D., Ph.D.; Javed Butler, M.D., M.P.H.; Gregg C. Fonarow, M.D.: John S. Ikonomidis, M.D., Ph.D.; Olga Khavjou, M.A.; Marvin A. Konstam, M.D.; Thomas M. Maddox, M.D., M.Sc.; Graham Nichol, M.D., M.P.H.; Michael Pham, M.D., M.P.H.; Ileana L. Piña, M.D., M.P.H.; and Justin G. Trogdon, Ph.D. Author disclosures are on the manuscript.

For the latest heart and stroke news, follow us on Twitter: @HeartNews.

The American Heart Association/American Stroke Association receives funding mostly from individuals. Foundations and corporations donate as well, and fund specific programs and events. Strict policies are enforced to prevent these relationships from influencing the association's science content. Financial information for the American Heart Association, including a list of contributions from pharmaceutical companies and device manufacturers, is available at http://www.heart.org/corporatefunding.

ELSE PRESS RELEASES FROM THIS DATE:

NASH diagnosis set to improve with non-invasive tool

2013-04-24

A Chinese study presented at the International Liver CongressTM 2013 has demonstrated the accuracy of a non-invasive test for non-alcoholic steatohepatitis (NASH) diagnosis. Non Alcoholic Fatty Liver disease (NAFLD) comprises two groups of patients; one group with simple steatosis which is relatively benign and one group with NASH which may progress to cirrhosis and hepatocellular carcinoma. Up to now the only means of distinguishing the two was to perform a liver biopsy. Phosphorus magnetic resonance spectroscopy (31P-MRS), which allows non-invasive in vivo assessment ...

Direct-acting antivirals now ready for prime time

2013-04-24

Amsterdam, The Netherlands, Wednesday 24 April 2013: New data from a number of clinical trials presented for the first time at the International Liver Congress™ 2013 demonstrate encouraging results in the use of new direct-acting antiviral agents (DAAs) for the treatment of hepatitis C. The following covers key results from the much anticipated Phase III trials conducted among HCV patients with a range of genotypes (GT 1 to 6) on DAA treatment. POSITRON A study of interferon (IFN)-ineligible, IFN-intolerant, or IFN-unwilling cirrhotic and non-cirrhotic GT 2 and ...

Battery and memory device in 1

2013-04-24

Resistive memory cells (ReRAM) are regarded as a promising solution for future generations of computer memories. They will dramatically reduce the energy consumption of modern IT systems while significantly increasing their performance. Unlike the building blocks of conventional hard disk drives and memories, these novel memory cells are not purely passive components but must be regarded as tiny batteries. This has been demonstrated by researchers of Jülich Aachen Research Alliance (JARA), whose findings have now been published in the prestigious journal Nature Communications. ...

New research findings on the brain's guardian cells

2013-04-24

Researcher Johan Jakobsson and his colleagues have now published their results in Nature Communications. "At present, researchers know very little about exactly how microglia work. At the same time, there is a lot of curiosity and high hopes among brain researchers that greater understanding of microglia could lead to entirely new drug development strategies for various brain diseases", says Johan Jakobsson, research group leader at the Division of Molecular Neurogenetics at Lund University. What the researchers have now succeeded in identifying is a deviation in the ...

Huddersfield scientist helps to reveal a link in the evolutionary chain

2013-04-24

An international team of scientists, including Dr Paul Brotherton from the University of Huddersfield, reveal that events after the initial migration of farmers into Europe had a major impact on the modern gene pool. The paper, published in Nature Communications, investigates a major component of the maternal population history of modern Europeans by focusing on haplogroup H mitochondrial genomes from ancient human remains. This genetic data is then compared with cultural changes taking place between the Early Neolithic (~5450 BC) and Bronze Age (~2200 BC) in Central Europe. ...

Microscopic dust particles found in underground railways may pose health risk

2013-04-24

New research from the University of Southampton has found that working or travelling on an underground railway for a sustained period of time could have health implications. Previously published work suggests that working in environments such as steel mills or welding plants, which are rich in airborne metals, like iron, copper and nickel, can have damaging effects on health. However, little research has been done on the effects of working in an underground railway environment – a similarly metal-rich environment – and results of studies that have been conducted are often ...

Video reveals cancer cells' Achilles' heel

2013-04-24

VIDEO: The Natural Killer white blood cell in red is drawn to the cancerous B cell which has been treated with rituximab. It latches on to the side of the cell... Click here for more information. Scientists from the Manchester Collaborative Centre for Inflammation Research (MCCIR) have discovered why a particular cancer drug is so effective at killing cells. Their findings could be used to aid the design of future cancer treatments. Professor Daniel Davis and his team ...

Important fertility mechanism discovered

2013-04-24

Scientists in Mainz and Aachen have discovered a new mechanism that controls egg cell fertility and that might have future therapeutic potential. It was revealed by Professor Dr. Walter Stöcker of the Institute of Zoology at Johannes Gutenberg University Mainz (JGU) that the blood protein fetuin-B plays an important and previously unknown role in the fertilization of oocytes. Fetuin-B, first identified in the year 2000, is formed in the liver and secreted into the blood stream. During a joint research project with researchers at RWTH Aachen University headed by Professor ...

Mild blast injury causes molecular changes in brain akin to Alzheimer, Pitt team says

2013-04-24

A multicenter study led by scientists at the University of Pittsburgh School of Medicine shows that mild traumatic brain injury after blast exposure produces inflammation, oxidative stress and gene activation patterns akin to disorders of memory processing such as Alzheimer's disease. Their findings were recently reported in the online version of the Journal of Neurotrauma. Blast-induced traumatic brain injury (TBI) has become an important issue in combat casualty care, said senior investigator Patrick Kochanek, M.D., professor and vice chair of critical care medicine ...

New LED streetlight design curbs light pollution

2013-04-24

WASHINGTON, April 24, 2013—Streetlights illuminate the night, shining upon roadways and sidewalks across the world, but these ubiquitous elements of the urban environment are notoriously inefficient and major contributors to light pollution that washes out the night sky. Recent innovations in light emitting diodes (LEDs) have improved the energy efficiency of streetlights, but, until now, their glow still wastefully radiated beyond the intended area. A team of researchers from Taiwan and Mexico has developed a new lighting system design that harnesses high-efficiency LEDs ...

Costs to treat heart failure expected to more than double by 2030

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: